Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 43 Carcinoma, Hepatocellular 41 Carcinoma, Non-Small-Cell Lung 17 Colorectal Neoplasms 14 Breast Neoplasms 14 Small Cell Lung Carcinoma 12 Sarcoma 11 Ovarian Neoplasms 11 Nasopharyngeal Carcinoma 11 Triple Negative Breast Neoplasms 10 Lung Neoplasms 10 Cholangiocarcinoma 10 Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 9 Osteosarcoma 8 Biliary Tract Neoplasms 8 Advanced Gastric Cancer 8 Neoplasms 6 Head and Neck Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Liver Neoplasms 5 Glioma 5 Drug-Related Side Effects and Adverse Reactions 4 Thyroid Neoplasms 3 Melanoma 3 Gastrointestinal Neoplasms 3

Interventions

pembrolizumab 1 olaparib 1 ceralasertib 1 apatinib 1 anlotinib 1 Immune Checkpoint Inhibitors 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × SCLC × apatinib × Clear all

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡